- Amended Statement of Ownership: Solicitation (SC 14D9/A)
December 24 2008 - 5:30PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Rule 14d-101)
Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934
(Amendment No. 6)
Memory Pharmaceuticals Corp.
(Name of Subject Company)
Memory Pharmaceuticals Corp.
(Name of Person Filing Statement)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
58606R403
(CUSIP Number of Class of Securities)
Vaughn M. Kailian
Chief Executive Officer
Memory Pharmaceuticals Corp.
100 Philips Parkway
Montvale, New Jersey 07645
(201) 802-7100
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications on Behalf of Person Filing Statement)
Copy to:
Ellen B. Corenswet, Esq.
J. D. Weinberg, Esq.
Covington & Burling LLP
The New York Times Building
620 Eighth Avenue
New York, New York 10018
(212) 841-1000
o
|
|
Check the box if the filing relates solely to preliminary
communications made before the commencement of a tender offer.
|
TABLE OF CONTENTS
This Amendment No. 6 (this
Amendment
) amends and supplements the Solicitation/Recommendation
Statement on Schedule 14D-9 initially filed on December 3, 2008, by Memory Pharmaceuticals Corp., a
Delaware corporation (
Memory
), as amended on December 4, 2008, December 5, 2008, December 15,
2008, December 18, 2008 and December 19, 2008 (the
Schedule 14D-9
). The Schedule 14D-9 relates
to the offer by 900 North Point Acquisition Corporation, a Delaware corporation and a direct
wholly-owned subsidiary of Hoffmann-La Roche Inc., a New Jersey corporation (
Roche
), to purchase,
at a price of $0.61 per share in cash, net to the seller, without interest and less any required
withholding taxes, all of the issued and outstanding shares of common stock of Memory, on the terms
and subject to the conditions specified in the offer to purchase dated December 3, 2008, and
related letter of transmittal, each filed as an exhibit to the Schedule TO filed by Roche with the
Securities and Exchange Commission on December 3, 2008.
Except as otherwise set forth below, the information set forth in the Schedule 14D-9 remains
unchanged and is incorporated herein by reference as relevant to the items in this Amendment.
Capitalized terms used but not otherwise defined herein have the meanings ascribed to such terms in
the Schedule 14D-9.
Item 8. Additional Information.
Item 8 of the Schedule 14D-9 is hereby further amended and supplemented by adding the
following language after the last paragraph under Exon-Florio Amendment on page 21 thereof:
On December 24, 2008, Memory was informed that CFIUS had completed its national security
review relating to Parents proposed acquisition of Memory and determined that there were no
unresolved national security concerns sufficient to warrant further action under Exon-Florio.
Accordingly, the condition to the Offer relating to the review by CFIUS of the proposed acquisition
has been satisfied.
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information
set forth in this statement is true, complete and correct.
|
|
|
|
|
|
Memory Pharmaceuticals Corp.
|
|
|
By:
|
/s/ Michael P. Smith
|
|
|
|
Name:
|
Michael P. Smith
|
|
|
|
Title:
|
Chief Financial Officer
|
|
|
Dated: December 24, 2008
Memory Pharmaceuticals Corp (MM) (NASDAQ:MEMY)
Historical Stock Chart
From Jul 2024 to Jul 2024
Memory Pharmaceuticals Corp (MM) (NASDAQ:MEMY)
Historical Stock Chart
From Jul 2023 to Jul 2024